2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

Abstract

Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

1 . A compound of formula I 
       
         
           
           
               
               
           
         
         wherein 
         each of R 0 , R 1 , and R 2  independently is hydrogen, —S(O) 0-2 NR 12 R 13 , —S(O) 0-2 R 13 , —NR 12 S(O) 0-2 R 13  or —C(O)NR 12 R 13 ; 
         R 3  is —S(O) 0-2 NR 12 R 13  or —NR 12 S(O) 0-2 R 13 ; 
         wherein R 12  is selected from hydrogen and C 1-6 alkyl; and R 13  is selected from hydrogen, C 1-6 alkyl and C 3-12 cycloalkyl; 
         R 4  is hydrogen; 
         each of R 5  and R 6  independently is hydrogen or halogen; 
         each of R 7 , R 8 , R 9 , and R 10  independently is ethoxy, ethyl, propyl, t-butyl, trifluoromethyl, nitrile, cyclobutyloxy, 2,2,2-trifluoroethoxy, isobutyloxy, t-butyloxy, isopropyloxy, methyl-amino-carbonyl, cyclopropyl-methoxy, dimethylamino-propyl-amino, methoxy-ethoxy, —XR 11 , —C(O)R 11  or —OXR 11 ; wherein X is a bond, methylene or ethylene; R 11  is selected from piperazinyl, piperidinyl, pyrrolidinyl, morpholino, azepanyl and 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl; wherein R 11  is optionally substituted by 1 to 3 radicals independently selected from methyl, isopropyl, acetyl, acetyl-methyl-amino, 3-dimethylamino-2,2-dimethyl-propylamino, ethyl-methyl-amino-ethoxy, diethyl-amino-ethoxy, amino-carbonyl, ethyl, 2-oxo-pyrrolidin-1-yl, pyrrolidinyl, pyrrolidinyl-methyl, piperidinyl optionally substituted with methyl or ethyl, morpholino, dimethylamino, dimethylamino-propyl-amino, methyl-amino and ethyl-amino; 
         wherein one of R 7 , R 8  and R 9  independently of each other can also be hydrogen; and 
         A is C; or 
         salts thereof; 
         with the proviso that said compound of Formula (I) is not 
       
       
         
           
           
               
               
           
         
         wherein Rx is 
       
       
         
           
           
               
               
           
         
       
     
     
         2 . The compound of  claim 1 , wherein
 each of R 0  or R 2  independently is hydrogen;   R 1  is hydrogen; and   R 3  is selected from dimethyl-sulfamoyl, isobutyl-sulfamoyl, methyl-sulfamoyl, ethyl-sulfamoyl, 1-ethyl-propyl-sulfamoyl, cyclopentyl-sulfamoyl, isopropyl-sulfamoyl, cyclopropyl-methyl-sulfamoyl or cyclobutyl-sulfamoyl.   
     
     
         3 . A pharmaceutical composition comprising a compound according to  claim 1 , as active ingredient together with one or more pharmaceutically acceptable diluents or carriers. 
     
     
         4 . A combination comprising a therapeutically effective amount of a compound according to  claim 1  and one or more further known drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders. 
     
     
         5 . A method for the treatment of breast tumor in a subject in need thereof which comprises administering an effective amount of a compound according to  claim 1 . 
     
     
         6 . A compound of Formula I′ 
       
         
           
           
               
               
           
         
         in which: 
         n′ is selected from 1 and 2; 
         R′ 1  is selected from pyridinyl, pyrazolyl and pyrimidinyl; each of which is substituted by 1 to 3 radicals independently selected from ethoxy, ethyl, propyl, methyl, t-butyl, trifluoromethyl, nitrile, cyclobutyloxy, 2,2,2-trifluoroethoxy, isobutyloxy, t-butyloxy, isopropyloxy, methyl-amino-carbonyl, cyclopropyl-methoxy, dimethylamino-propyl-amino, methoxy-ethoxy, —X′R′ 4 , —C(O)R′ 4  and —OX′R′ 4 ; wherein X′ is a bond, methylene or ethylene; R′ 4  is selected from piperazinyl, piperidinyl, pyrrolidinyl, morpholino, azepanyl and 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl; wherein R′ 4  is optionally substituted by 1 to 3 radicals independently selected from methyl, isopropyl, acetyl, acetyl-methyl-amino, 3-dimethylamino-2,2-dimethyl-propylamino, ethyl-methyl-amino-ethoxy, diethyl-amino-ethoxy, amino-carbonyl, ethyl, 2-oxo-pyrrolidin-1-yl, pyrrolidinyl, pyrrolidinyl-methyl, piperidinyl optionally substituted with methyl or ethyl, morpholino, dimethylamino, dimethylamino-propyl-amino, methyl-amino and ethyl-amino. 
         R′ 2  is selected from hydrogen and halo; and 
         R 3  is selected from dimethyl-sulfamoyl, isobutyl-sulfamoyl, methyl-sulfamoyl, ethyl-sulfamoyl, 1-ethyl-propyl-sulfamoyl, cyclopentyl-sulfamoyl, isopropyl-sulfamoyl, cyclopropyl-methyl-sulfamoyl or cyclobutyl-sulfamoyl. 
       
     
     
         7 . A pharmaceutical composition comprising a compound according to  claim 6 , as active ingredient together with one or more pharmaceutically acceptable diluents or carriers. 
     
     
         8 . A combination comprising a therapeutically effective amount of a compound according to  claim 6  and one or more further known drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders. 
     
     
         9 . A method for the treatment of breast tumor in a subject in need thereof which comprises administering an effective amount of a compound according to  claim 6 .